Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ruxolitinib for Chuvash Polycythemia

Expanded access is currently available for this treatment.
Verified January 2016 by Washington University School of Medicine
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01730755
First received: November 7, 2012
Last updated: January 6, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: Expanded access is currently available for this treatment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given